Developer docs
API playgroundTry for free, no card

Search company profiles

Transpharmation

Full company profile

uuid00088uc

Namestring
Transpharmation
Legal namestring
Transpharmation
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Transpharmation is a privately held preclinical Contract Research Organization (CRO) headquartered in Dublin, Ireland, with commercial operations spanning North America and Europe. Founded in 2010, the company specializes in translational neuroscience drug discovery services, addressing a documented industry challenge of translating preclinical animal-model findings into clinical success for pharmaceutical and biotech sponsors.

The company operates more than 30 service modules spanning CNS disorders (Alzheimer's, Parkinson's, epilepsy, schizophrenia, depression/anxiety, migraine, multiple sclerosis, essential tremor), pain (inflammatory, neuropathic, osteoarthritic), inflammation, metabolic disease, dermatology, abuse liability, psychedelics, medical cannabis, and veterinary research. Its flagship technical asset is access to the world's largest laboratory beagle colony, used to study naturally developing age-related diseases including Alzheimer's-like cognitive decline and osteoarthritic pain. Supporting platforms include the Operant Platform for behavioral testing, EEG and imaging capabilities, PK-Bridge for translational PK/PD linking, the SPIDAR platform for proprietary discovery methodologies, and PXB Mouse Studies for humanized-liver metabolism work. Bioanalytical, molecular biomarker, and safety study services complement the in vivo offering.

Revenue is generated through fee-for-service study contracts with pharmaceutical and biotechnology clients, with pricing determined by study scope, complexity, and duration on a quote basis. The go-to-market model is sales-led B2B, executed through dedicated North American and European phone lines and website contact forms directed at enterprise pharma and biotech buyers. The company is privately held, with no disclosed funding rounds, institutional investors, M&A activity, or named customers in the available data, and headcount sits in the 11-50 range.

Short descriptiontext

Transpharmation is a privately held preclinical neuroscience CRO headquartered in Dublin, Ireland, serving pharmaceutical and biotechnology drug discovery teams globally with animal-model studies, EEG, imaging, and PK/PD services leveraging the world's largest laboratory beagle colony.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
preclinical neuroscience research, contract research organization, drug discovery services, translational biology, CNS drug development
Industry2 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service preclinical neuroscience research contracts with pharmaceutical and biotech companies. Services provided across multiple therapeutic areas including CNS disorders, pain, inflammation, and metabolic diseases. Revenue generated through study contracts with defined deliverables.

transpharmation.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Transpharmation is a preclinical contract research organization (CRO) providing translational biology and drug discovery services to pharmaceutical and biotechnology companies. Services span 30+ therapeutic areas including Alzheimer's, Parkinson's, epilepsy, migraine, depression/anxiety, schizophrenia, multiple sclerosis, pain disorders, inflammation, and metabolic diseases, using validated animal models and proprietary platforms such as the Operant Platform, PK-Bridge, and SPIDAR. Its unique asset is access to the world's largest laboratory beagle colony, enabling studies of naturally developing age-related conditions such as Alzheimer's-like cognitive decline and osteoarthritic pain.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Access to the largest laboratory beagle colony in the world
+1 more record
Product overview1 text field

Transpharmation is a global preclinical neuroscience Contract Research Organization (CRO) providing translational biology services for drug discovery. The company operates a portfolio of specialized service modules spanning over 30 therapeutic areas including Alzheimer's Disease, Parkinson's Disease, Pain disorders, Psychiatric conditions, Epilepsy, and Multiple Sclerosis. Key platforms include the Operant Platform for behavioral research, PK-Bridge for translational PK/PD linking, and SPIDAR for specialized discovery methodologies. The company is distinguished by access to the largest laboratory beagle colony in the world, enabling studies of naturally developing age-related diseases. Services are delivered as individual modules or integrated programs from start to finish for pharmaceutical and biotech clients.

Product and service30 records
1Alzheimer's Disease Research Services
CategoryTherapeutic area research service
2Parkinson's Disease Research Services
CategoryTherapeutic area research service
3Epilepsy Research Services
CategoryTherapeutic area research service
4Depression/Anxiety Research Services
CategoryTherapeutic area research service
5Schizophrenia Research Services
CategoryTherapeutic area research service
6Migraine Research Services
CategoryTherapeutic area research service
7Multiple Sclerosis Research Services
CategoryTherapeutic area research service
8Essential Tremor Research Services
CategoryTherapeutic area research service
9Abuse Liability / Substance Use Disorders Services
CategoryTherapeutic area research service
10Medical Cannabis Research Services
CategoryTherapeutic area research service
11Psychedelics Research Services
CategoryTherapeutic area research service
12Neuropathic Pain Services
CategoryTherapeutic area research service
13Inflammatory Pain Services
CategoryTherapeutic area research service
14Osteoarthritis Research Services
CategoryTherapeutic area research service
15Inflammation Research Services
CategoryTherapeutic area research service
16Metabolic Disorders Services
CategoryTherapeutic area research service
17Dermatology Services
CategoryTherapeutic area research service
18Veterinary Research Services
CategoryTherapeutic area research service
19Operant Platform
CategoryProprietary research platform
20PK-Bridge
CategoryProprietary research platform
21SPIDAR
CategoryProprietary research platform
22PK/PD Studies
CategorySpecialized research service
23CNS Drug Disposition Services
CategorySpecialized research service
24Safety Studies
CategorySpecialized research service
25Bioanalytical Studies
CategorySpecialized research service
26Molecular Biomarkers Services
CategorySpecialized research service
27Cognitive Assessment Services
CategorySpecialized research service
28EEG Services
CategorySpecialized research service
29Imaging Services
CategorySpecialized research service
30PXB Mouse Studies
CategorySpecialized research service
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global mega-CRO offering end-to-end preclinical and clinical services including extensive CNS/neuroscience capabilities. Comparable as the incumbent broad-line CRO against which specialty neuroscience CROs like Transpharmation compete for the same pharma wallet.

TypeBroad incumbent
Description

Division of Eurofins Scientific providing preclinical discovery and pharmacology services including CNS models. Operates at much larger scale than Transpharmation but competes for similar preclinical outsourcing contracts.

TypeDirect peer
Description

US-based preclinical CRO specializing in CNS/neuroscience drug discovery using proprietary behavioral platforms (e.g., SmartCube). Directly comparable to Transpharmation as a specialty neuroscience preclinical CRO serving pharma/biotech with in vivo models and translational biology.

TypeDirect peer
Description

US-based preclinical CRO and research models provider with significant CNS and animal model capabilities, including contract research services. Directly comparable as a specialized preclinical CRO serving pharma/biotech with in vivo pharmacology studies.

TypeDirect peer
Description

French preclinical CRO offering behavioral pharmacology and CNS efficacy/safety models for pharma drug discovery. Highly comparable to Transpharmation in scope — specialized neuroscience and pain models with global pharma client base and fee-for-service CRO model.

TypeDirect peer
Description

UK-based integrated drug discovery CRO with CNS and translational pharmacology capabilities. Comparable mid-size specialty CRO serving pharma/biotech preclinical outsourcing, with similar therapeutic area breadth including neuroscience.

TypeBroad incumbent
Description

China-headquartered global CRO/CDMO with large preclinical and CNS research capabilities. A broad incumbent competitor in translational biology services competing with Transpharmation for global pharma preclinical outsourcing dollars.

TypeDirect peer
Description

Global preclinical CRO with translational drug discovery and oncology/CNS capabilities, acquired by JSR Corporation. Comparable to Transpharmation in offering translational preclinical services to pharma/biotech across multiple therapeutic areas.

TypeBroad incumbent
Description

One of the largest global CROs offering comprehensive preclinical and clinical services with neuroscience capabilities. An incumbent competitor that competes for the same translational research budgets as Transpharmation.

TypeEmerging player
Description

Growing preclinical CRO focused on biologics characterization and preclinical services. Less CNS-specialized than Transpharmation but comparable as a smaller specialty CRO competing for outsourced preclinical work from biotech clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Transpharmation

Preclinical Contract Research Servicestranspharmation.co.uk

Transpharmation is a privately held preclinical neuroscience CRO headquartered in Dublin, Ireland, serving pharmaceutical and biotechnology drug discovery teams globally with animal-model studies, EEG, imaging, and PK/PD services leveraging the world's largest laboratory beagle colony.

What Transpharmation does

Transpharmation is a privately held preclinical Contract Research Organization (CRO) headquartered in Dublin, Ireland, with commercial operations spanning North America and Europe. Founded in 2010, the company specializes in translational neuroscience drug discovery services, addressing a documented industry challenge of translating preclinical animal-model findings into clinical success for pharmaceutical and biotech sponsors.

The company operates more than 30 service modules spanning CNS disorders (Alzheimer's, Parkinson's, epilepsy, schizophrenia, depression/anxiety, migraine, multiple sclerosis, essential tremor), pain (inflammatory, neuropathic, osteoarthritic), inflammation, metabolic disease, dermatology, abuse liability, psychedelics, medical cannabis, and veterinary research. Its flagship technical asset is access to the world's largest laboratory beagle colony, used to study naturally developing age-related diseases including Alzheimer's-like cognitive decline and osteoarthritic pain. Supporting platforms include the Operant Platform for behavioral testing, EEG and imaging capabilities, PK-Bridge for translational PK/PD linking, the SPIDAR platform for proprietary discovery methodologies, and PXB Mouse Studies for humanized-liver metabolism work. Bioanalytical, molecular biomarker, and safety study services complement the in vivo offering.

Revenue is generated through fee-for-service study contracts with pharmaceutical and biotechnology clients, with pricing determined by study scope, complexity, and duration on a quote basis. The go-to-market model is sales-led B2B, executed through dedicated North American and European phone lines and website contact forms directed at enterprise pharma and biotech buyers. The company is privately held, with no disclosed funding rounds, institutional investors, M&A activity, or named customers in the available data, and headcount sits in the 11-50 range.

Transpharmation firmographics

Firmographics
Name
Transpharmation
Legal name
Transpharmation
Website
https://transpharmation.co.uk
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
Transpharmation is a privately held preclinical neuroscience CRO headquartered in Dublin, Ireland, serving pharmaceutical and biotechnology drug discovery teams globally with animal-model studies, EEG, imaging, and PK/PD services leveraging the world's largest laboratory beagle colony.
Ownership category
akta.pro rank

Transpharmation industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Preclinical neuroscience research
  • Contract research organization
  • Drug discovery services
  • Translational biology
  • CNS drug development

Where Transpharmation is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

Transpharmation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services: Fee-for-service preclinical neuroscience research contracts with pharmaceutical and biotech companies. Services provided across multiple therapeutic areas including CNS disorders, pain, inflammation, and metabolic diseases. Revenue generated through study contracts with defined deliverables.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Transpharmation product offering

Product offering

Core offering

Transpharmation is a preclinical contract research organization (CRO) providing translational biology and drug discovery services to pharmaceutical and biotechnology companies. Services span 30+ therapeutic areas including Alzheimer's, Parkinson's, epilepsy, migraine, depression/anxiety, schizophrenia, multiple sclerosis, pain disorders, inflammation, and metabolic diseases, using validated animal models and proprietary platforms such as the Operant Platform, PK-Bridge, and SPIDAR. Its unique asset is access to the world's largest laboratory beagle colony, enabling studies of naturally developing age-related conditions such as Alzheimer's-like cognitive decline and osteoarthritic pain.

Product overview

Transpharmation is a global preclinical neuroscience Contract Research Organization (CRO) providing translational biology services for drug discovery. The company operates a portfolio of specialized service modules spanning over 30 therapeutic areas including Alzheimer's Disease, Parkinson's Disease, Pain disorders, Psychiatric conditions, Epilepsy, and Multiple Sclerosis. Key platforms include the Operant Platform for behavioral research, PK-Bridge for translational PK/PD linking, and SPIDAR for specialized discovery methodologies. The company is distinguished by access to the largest laboratory beagle colony in the world, enabling studies of naturally developing age-related diseases. Services are delivered as individual modules or integrated programs from start to finish for pharmaceutical and biotech clients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alzheimer's Disease Research Services
  • Parkinson's Disease Research Services
  • Epilepsy Research Services
  • Depression/Anxiety Research Services
  • Schizophrenia Research Services
  • Migraine Research Services
  • Multiple Sclerosis Research Services
  • Essential Tremor Research Services
  • Abuse Liability / Substance Use Disorders Services
  • Medical Cannabis Research Services
  • Psychedelics Research Services
  • Neuropathic Pain Services
  • Inflammatory Pain Services
  • Osteoarthritis Research Services
  • Inflammation Research Services
  • Metabolic Disorders Services
  • Dermatology Services
  • Veterinary Research Services
  • Operant Platform
  • PK-Bridge
  • SPIDAR
  • PK/PD Studies
  • CNS Drug Disposition Services
  • Safety Studies
  • Bioanalytical Studies
  • Molecular Biomarkers Services
  • Cognitive Assessment Services
  • EEG Services
  • Imaging Services
  • PXB Mouse Studies

Quantifiable outcome

  • Access to the largest laboratory beagle colony in the world
  • +1 more outcomes

Companies that use Transpharmation

Customer profile

Segments3 records

Ideal customer profiles2 records

Transpharmation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Transpharmation partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Transpharmation competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Global mega-CRO offering end-to-end preclinical and clinical services including extensive CNS/neuroscience capabilities. Comparable as the incumbent broad-line CRO against which specialty neuroscience CROs like Transpharmation compete for the same pharma wallet.
  • Eurofins Discovery: Division of Eurofins Scientific providing preclinical discovery and pharmacology services including CNS models. Operates at much larger scale than Transpharmation but competes for similar preclinical outsourcing contracts.
  • WuXi AppTec: China-headquartered global CRO/CDMO with large preclinical and CNS research capabilities. A broad incumbent competitor in translational biology services competing with Transpharmation for global pharma preclinical outsourcing dollars.
  • Labcorp Drug Development (formerly Covance): One of the largest global CROs offering comprehensive preclinical and clinical services with neuroscience capabilities. An incumbent competitor that competes for the same translational research budgets as Transpharmation.

Direct peers

  • PsychoGenics: US-based preclinical CRO specializing in CNS/neuroscience drug discovery using proprietary behavioral platforms (e.g., SmartCube). Directly comparable to Transpharmation as a specialty neuroscience preclinical CRO serving pharma/biotech with in vivo models and translational biology.
  • Inotiv: US-based preclinical CRO and research models provider with significant CNS and animal model capabilities, including contract research services. Directly comparable as a specialized preclinical CRO serving pharma/biotech with in vivo pharmacology studies.
  • Porsolt: French preclinical CRO offering behavioral pharmacology and CNS efficacy/safety models for pharma drug discovery. Highly comparable to Transpharmation in scope — specialized neuroscience and pain models with global pharma client base and fee-for-service CRO model.
  • Sygnature Discovery: UK-based integrated drug discovery CRO with CNS and translational pharmacology capabilities. Comparable mid-size specialty CRO serving pharma/biotech preclinical outsourcing, with similar therapeutic area breadth including neuroscience.
  • Crown Bioscience: Global preclinical CRO with translational drug discovery and oncology/CNS capabilities, acquired by JSR Corporation. Comparable to Transpharmation in offering translational preclinical services to pharma/biotech across multiple therapeutic areas.

Emerging players

  • Bionova Scientific: Growing preclinical CRO focused on biologics characterization and preclinical services. Less CNS-specialized than Transpharmation but comparable as a smaller specialty CRO competing for outsourced preclinical work from biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Transpharmation social profiles

Digital presence

Transpharmation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Transpharmation leadership team

Management profile

Number of profiles

Transpharmation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Transpharmation M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transpharmation

What does Transpharmation do?

Transpharmation is a preclinical contract research organization (CRO) providing translational biology and drug discovery services to pharmaceutical and biotechnology companies. Services span 30+ therapeutic areas including Alzheimer's, Parkinson's, epilepsy, migraine, depression/anxiety, schizophrenia, multiple sclerosis, pain disorders, inflammation, and metabolic diseases, using validated animal models and proprietary platforms such as the Operant Platform, PK-Bridge, and SPIDAR. Its unique asset is access to the world's largest laboratory beagle colony, enabling studies of naturally developing age-related conditions such as Alzheimer's-like cognitive decline and osteoarthritic pain.

Is Transpharmation a public or private company?

Transpharmation is a private company. It is classified as unknown and is currently operating.

When was Transpharmation founded?

Transpharmation was founded in 2002. It employs 101 to 250 people.

Where is Transpharmation based?

Transpharmation is headquartered in London, United Kingdom, in the Europe region.

How does Transpharmation make money?

One revenue line is on record: contract Research Services.

Who are Transpharmation's main competitors?

Broad incumbents on record are Charles River Laboratories, Eurofins Discovery, WuXi AppTec and Labcorp Drug Development (formerly Covance). Direct peers are PsychoGenics, Inotiv, Porsolt, Sygnature Discovery and Crown Bioscience. Bionova Scientific is listed as an emerging player.

Does Transpharmation have an API?

No public API is recorded for Transpharmation.

What industry is Transpharmation in?

Transpharmation's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterTranspharmation acquires OrganoTherapeutics to advance neurodegenerative disease researchTranspharmation acquired OrganoTherapeutics SARL, a Luxembourg-based company specializing in patient-derived organoid technologies for neurodegenerative and CNS disorders. The acquisition expands Transpharmation's translational CRO services to include human tissues and systems, complementing its preclinical pharmacology expertise. No financial terms were disclosed.AktienTranspharmation Ltd. gibt strategische Übernahme von OrganoTherapeutics SARL bekanntTranspharmation Ltd. announced its strategic acquisition of OrganoTherapeutics SARL, a provider of patient-derived organoid technologies for neurodegenerative disease research. The acquisition aims to build translational CRO services using human tissue models, with OrganoTherapeutics continuing as a subsidiary. CEO Mark Duxon cited the need for better drug prediction before clinical trials.PR NewswireTranspharmation Ltd. gibt strategische Übernahme von OrganoTherapeutics SARL bekanntTranspharmation Ltd. announced its acquisition of Luxembourg-based OrganoTherapeutics SARL, a provider of patient-derived brain organoids for neurodegenerative disease research. The deal combines Transpharmation's preclinical pharmacology with OrganoTherapeutics' organoid models for Parkinson's, Huntington's, ALS, and other conditions. The combined entity aims to offer human-relevant models alongside traditional preclinical platforms.LelezardTranspharmation Ltd. annonce l'acquisition stratégique d'OrganoTherapeutics SARLTranspharmation Ltd. announced its strategic acquisition of Luxembourg-based OrganoTherapeutics SARL, a leader in patient-derived organoid technologies for neurodegenerative diseases. The deal aims to combine Transpharmation's preclinical pharmacology with OrganoTherapeutics' organoid models to improve drug prediction and accelerate research in conditions like Parkinson's and Alzheimer's.PR NewswireTranspharmation Ltd. annonce l'acquisition stratégique d'OrganoTherapeutics SARLTranspharmation Ltd. acquired Luxembourg-based OrganoTherapeutics SARL, a developer of patient-derived organoid models for neurodegenerative diseases. The acquisition aims to combine Transpharmation's preclinical pharmacology with OrganoTherapeutics' organoid technology to improve drug prediction. OrganoTherapeutics will remain a subsidiary, with a smooth transition.PR NewswireTranspharmation Ltd. anuncia la adquisición estratégica de OrganoTherapeutics SARLTranspharmation Ltd. acquired Luxembourg-based OrganoTherapeutics SARL, a company developing patient-derived organoid models for neurodegenerative diseases. The acquisition aims to integrate human tissue-based research with Transpharmation's preclinical services, offering non-animal models for drug development. OrganoTherapeutics will remain a subsidiary under a smooth transition.NewswireTranspharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARLTranspharmation Ltd. acquired Luxembourg-based OrganoTherapeutics SARL, a developer of patient-derived brain organoid models for neurodegenerative diseases. The acquisition adds human tissue and systems capabilities to Transpharmation's preclinical contract research services. OrganoTherapeutics will operate as a subsidiary, combining both companies' expertise.AktienTranspharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARLTranspharmation Ltd. acquired OrganoTherapeutics SARL, a provider of patient-derived organoid technologies for neurodegenerative disease research. The acquisition expands Transpharmation's translational CRO services to include human tissue models, aiming to improve drug prediction before clinical trials. OrganoTherapeutics will operate as a subsidiary with a seamless transition.PR NewswireTranspharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARLTranspharmation Ltd. acquired Luxembourg-based OrganoTherapeutics SARL, a developer of patient-derived brain organoid models for neurodegenerative diseases. The acquisition aims to combine Transpharmation's preclinical pharmacology with OrganoTherapeutics' organoid technology to offer non-animal models for drug discovery. OrganoTherapeutics will operate as a subsidiary under Transpharmation.PR NewswireTranspharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARLTranspharmation Ltd. acquired Luxembourg-based OrganoTherapeutics SARL, a developer of patient-derived brain organoid models for neurodegenerative diseases. The acquisition adds human tissue and systems to Transpharmation's preclinical contract research services, aiming to improve drug discovery prediction. OrganoTherapeutics will operate as a subsidiary under Transpharmation.